Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Scarlet-2: A Randomized, Double-Blind,Placebo-Controlled, Phase 3 Study to Assess The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy

NCT03517501 is registered in ClinicalTrials.gov with Asahi Kasei Pharma America Corporation as lead sponsor.

NCT NCT03517501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03517501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Scarlet-2: A Randomized, Double-Blind,Placebo-Controlled, Phase 3 Study to Assess The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy
Lead sponsor
Asahi Kasei Pharma America Corporation
Phase
Phase 3
Overall status
Withdrawn
Start date
July 31, 2019
Completion date
May 31, 2023
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

sepsis and coagulopathy